The I.M. Rosenzweig Junior Investigator Award Winners​

The I.M. Rosenzweig Junior Investigator Award was established to encourage researchers to maintain and enhance their interest in PF research during the early stages of their academic career. 

The Albert Rose Established Investigator Award Winners

Created to allow established investigators to explore novel, innovative areas of research, the Albert Rose Established Investigator Award provides critical support to the development of new projects, and enables the investigator to pursue additional funding through the National Institutes of Health or other agencies. Two $50,000 grants are awarded per annual cycle, disbursed over a two-year period.

Jonathan Kropski, MD

Apr 19, 2021, 16:26 PM
Title : Jonathan Kropski, MD
First Name : Jonathan
Middle Name :
Last Name : Kropski, MD
Position :
University : Vanderbilt University
Proposal Title : "RTEL1 and DNA Damage Signaling in Pulmonary Fibrosis"
Proposal Funder : the NYC Run-Walk-Hike for Pulmonary Fibrosis.
Dr. Kropski is an assistant professor of medicine in the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt University in Nashville, Tennessee. He obtained his undergraduate degree from Davidson College and completed his medical education, internal medicine residency, and pulmonary/critical care fellowship at Vanderbilt. Dr. Kropski’s research interest focuses on determining the molecular mechanisms that mediate the early pathogenesis of pulmonary fibrosis, with an emphasis on the role of genetic factors that influence alveolar epithelial injury and repair. As a fellow working under Dr. Timothy Blackwell, Dr. Kropski identified mutations in DKC1 and RTEL1 as the basis for disease in some families with pulmonary fibrosis. His independent work now utilizes cell and animal-based models to determine the mechanisms through which these and other genetic risk factors for pulmonary fibrosis contribute to the development of disease. His ultimate goal is to use genetic and genomic profiling to develop rational and specific therapies for patients with pulmonary fibrosis.